 "Cipla dips 7% after Pithampur unit receives 8 USFDA observations")
Shares of Cipla dipped 7 per cent to Rs 956.20 on the BSE in Monday’s intra-day trade after the company said that the United States Food and Drug Administration (USFDA) issued Form 483 with 8 observations after the inspection of its Pithampur manufacturing facilities.
USFDA conducted a current Good Manufacturing Practices (cGMP) inspection at the company’s Pithampur manufacturing facility from 6th - 17th February, 2023, Cipla said in an exchange filing.
On conclusion of the inspection, the company has received 8 inspectional observations in Form 483. The company will work closely with the USFDA and is committed to
USFDA conducted a current Good Manufacturing Practices (cGMP) inspection at the company’s Pithampur manufacturing facility from 6th - 17th February, 2023, Cipla said in an exchange filing.
On conclusion of the inspection, the company has received 8 inspectional observations in Form 483. The company will work closely with the USFDA and is committed to
